Sonara Health is on a mission to end the opioid epidemic and save lives! Nearly 100,000 people died of an opioid overdose last year, and approximately 12 million Americans misuse opioids. Sonara Health partners with federally regulated opioid treatment programs (OTPs) to help make treatment more accessible than illicit opioids. Sonara is a patent-pending, remote dosing system developed by physicians to establish trust and add assurance to the take-home methadone dosing process. Sonara provides OTPs with the confidence they need to approve more take-home doses responsibly, to improve quality of life for patients and expand treatment accessibility for those who live farther away from clinics. Notable investors in Mark Cuban and First Trust Capital.

Many patients at opioid treatment programs require daily visits, and most of these clinics are not set up to utilize remote treatment options. Sonara, our first product, is a telehealth platform designed to meet the highly specific needs of opioid treatment clinics and their patients. By increasing access to care for patients, financial incentives for clinics, and savings for payors, our platform will revolutionize the delivery of care for opioid use disorder.

Sonara is a medication adherence ecosystem that makes Methadone based treatment for Opioid Use Disorder more accessible and convenient for patients through a patented, tamper-aware medication monitoring system. 

We work with patients and their care teams to deliver a more sustainable treatment, improving patient retention and satisfaction in Opioid Treatment Programs. 

Brightside Health provides safe and effective mental health care, for individuals with varying levels of depression, anxiety, and other mood disorders, up to those with suicidal intent.

In the months to come, Sonara Health was formed under Dr. Giles’ philosophy that facilitating humanized, compassionate and trustworthy interactions between OTP patients and providers will lead to greater outcomes and have a noticeable positive impact on the opioid epidemic.    

Brightside has developed a purpose-built EHR that incorporates anytime messaging, best practices, advanced workflow, risk assessment, strong security protocols, and clinical decision support to help providers effeciently and securely practice to the top of their license.

At Brightside Health, we have developed innovative solutions that address the full spectrum of mental health needs, particularly for underserved and high-severity populations. Our comprehensive telepsychiatry platform seamlessly integrates with health plans, hospitals, and referral networks, delivering accessible, high-quality care tailored to conditions ranging from mild to severe, including elevated suicide risk and substance use disorders.

Our comprehensive platform stands out as the only telemental health provider specifically designed to treat complex, hard-to-manage cases, offering appointments within 24 hours. Our tiered levels of care enhance this approach by directing individuals with positive suicidal ideation screens to our Suicide Prevention Program for rapid referrals, reducing emergency department admissions and readmissions.

In line with our commitment to supporting high-risk populations, Brightside serves teens and collaborates with Medicaid, Medicare, and Exchange plans to ensure that care reaches those who need it most. Our partner-focused reporting includes closed-loop outcomes data to drive optimal revenue, customized dashboards for enhanced visibility, and supplemental data files that bridge quality gaps and support holistic patient care.

Among our proprietary innovations is PrecisionRx, a groundbreaking tool that analyzes hundreds of individual data points to recommend medications with the highest likelihood of effectiveness and tolerance. This clinical decision support tool allows our providers to optimize medication choices from the outset, resulting in a 70% response rate for first-cycle treatments—double the industry standard. Additionally, we leverage AI-driven tools to streamline remote patient monitoring, risk assessment, and both patient and clinical workflows, enhancing provider efficiency, reducing burnout, and enabling our clinicians to focus on delivering high-quality, personalized care.

We are also committed to peer-reviewed research, having published 12 studies to date. Example results include:  

• A study in BMC Psychiatry showed that 86% of patients using PrecisionRx with remote monitoring achieved clinically significant improvement at 12 weeks, and 71% reached remission, underscoring the tool’s effectiveness in improving patient outcomes.
• Research published in Cureus revealed that nearly 80% of patients on Brightside Health’s platform experienced a meaningful reduction in symptoms, compared to 52% of those receiving treatment as usual, highlighting the effectiveness of Brightside Health’s care model. 
• Brightside Health’s latest research, published in JMIR Mental Health, demonstrated that OpenAI’s GPT-4 can predict mental health crises with similar accuracy to trained clinicians, but with higher sensitivity and lower specificity. This highlights the potential of AI to enhance clinical decision making and improve the speed and quality of care and reinforces Brightside Health’s approach to leveraging AI and data to deliver more effective mental health treatment. 
• In JMIR Formative Research, Brightside Health examined results from over 8,500 U.S.-based adults who either received at least 12 weeks of treatment, or engaged on our platform without receiving care. Among participants, those receiving care through Brightside Health’s Suicide Prevention Program were 4.3 times more likely to experience remission than the control group.